|
TW467902B
(en)
*
|
1996-07-31 |
2001-12-11 |
Bristol Myers Squibb Co |
Diphenyl heterocycles as potassium channel modulators
|
|
JP2002501926A
(ja)
*
|
1998-01-29 |
2002-01-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
ジアリール１、３、４−オキサジアゾロンのホスフェート誘導体
|
|
EP1056730A4
(en)
*
|
1998-01-29 |
2003-01-02 |
Bristol Myers Squibb Co |
Diaryl-1,3,4-oxadiazolone benzoate
|
|
ID26909A
(id)
*
|
1998-01-29 |
2001-02-15 |
Bristol Myers Squibb Co |
Turunan-turunan 1,3,4-oksadiazolon
|
|
JP2003525199A
(ja)
*
|
1998-01-29 |
2003-08-26 |
ブリストル−マイヤーズ スクイブ カンパニー |
ジアリール１，３，４−オキサジアゾロンアミノ酸誘導体
|
|
DE19816882A1
(de)
*
|
1998-04-17 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Triazolone mit neuroprotektiver Wirkung
|
|
US6911462B2
(en)
*
|
1998-05-22 |
2005-06-28 |
Avanir Pharmaceuticals |
Benzimidazole compounds for regulating IgE
|
|
US6919366B2
(en)
*
|
1998-05-22 |
2005-07-19 |
Avanir Pharmaceuticals |
Benzimidazole derivatives as modulators of IgE
|
|
SE9802937D0
(sv)
*
|
1998-09-01 |
1998-09-01 |
Astra Pharma Prod |
Novel compounds
|
|
US6194458B1
(en)
|
1998-10-30 |
2001-02-27 |
Merck & Co., Inc. |
Benzamide potassium channel inhibitors
|
|
US6632836B1
(en)
|
1998-10-30 |
2003-10-14 |
Merck & Co., Inc. |
Carbocyclic potassium channel inhibitors
|
|
US6303637B1
(en)
|
1998-10-30 |
2001-10-16 |
Merck & Co., Inc. |
Heterocyclic potassium channel inhibitors
|
|
PL349097A1
(en)
*
|
1999-01-29 |
2002-07-01 |
Bristol Myers Squibb Co |
Carbamate derivatives of diaryl 1,3,4-oxadiazolone
|
|
US6297241B1
(en)
|
1999-01-29 |
2001-10-02 |
Bristol-Myers Squibb Company |
Carbamate derivatives of diaryl 1,3,4-oxadiazolone
|
|
GB9915414D0
(en)
*
|
1999-07-01 |
1999-09-01 |
Glaxo Group Ltd |
Medical use
|
|
US7018979B1
(en)
|
2000-01-26 |
2006-03-28 |
Cedars-Sinai Medical Center |
Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
|
US20050153940A1
(en)
*
|
2000-01-26 |
2005-07-14 |
Cedars-Sinai Medical Center |
Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
|
GB2361003A
(en)
*
|
2000-04-07 |
2001-10-10 |
Astrazeneca Ab |
Novel compounds
|
|
JP2004511457A
(ja)
*
|
2000-10-13 |
2004-04-15 |
ブリストル−マイヤーズ スクイブ カンパニー |
高い細胞内カルシウム濃度の条件下で機能する選択的マキシ−ｋカリウムチャネル・オープナー、その方法および用途
|
|
DE10056344A1
(de)
*
|
2000-11-14 |
2002-05-16 |
Degussa |
n-Propylethoxysiloxane, Verfahren zu deren Herstellung und deren Verwendung
|
|
DE10058461A1
(de)
*
|
2000-11-24 |
2002-09-19 |
Bayer Ag |
Substituierte Cyclohexanderivate und ihre Verwendung
|
|
US6855829B2
(en)
|
2001-02-20 |
2005-02-15 |
Bristol-Myers Squibb Company |
3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
|
|
WO2002072090A1
(en)
*
|
2001-03-12 |
2002-09-19 |
Avanir Pharmaceuticals |
Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
|
|
WO2002083111A2
(en)
*
|
2001-04-16 |
2002-10-24 |
Tanabe Seiyaku Co., Ltd. |
Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
|
|
US7022480B1
(en)
|
2001-10-11 |
2006-04-04 |
The Regents Of The University Of California |
Exons of the hSKCa3/KCNN3 gene
|
|
US7211561B2
(en)
*
|
2001-10-12 |
2007-05-01 |
Cedars-Sinai Medical Center |
Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
|
|
US6613786B2
(en)
|
2001-11-02 |
2003-09-02 |
Bristol-Myers Squibb Company |
Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
|
|
US7846671B2
(en)
*
|
2002-01-28 |
2010-12-07 |
Bristol-Myers Squibb Company |
Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence
|
|
TW200304820A
(en)
*
|
2002-03-25 |
2003-10-16 |
Avanir Pharmaceuticals |
Use of benzimidazole analogs in the treatment of cell proliferation
|
|
AU2003270426A1
(en)
|
2002-09-12 |
2004-04-30 |
Avanir Pharmaceuticals |
PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
|
|
TWI276631B
(en)
*
|
2002-09-12 |
2007-03-21 |
Avanir Pharmaceuticals |
Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
|
|
TWI271402B
(en)
*
|
2002-10-15 |
2007-01-21 |
Tanabe Seiyaku Co |
Large conductance calcium-activated K channel opener
|
|
TW200505441A
(en)
|
2003-03-24 |
2005-02-16 |
Hoffmann La Roche |
Non-nucleoside reverse transcriptase inhibitorsⅠ
|
|
CN1826111A
(zh)
*
|
2003-04-10 |
2006-08-30 |
阿文尼尔药品公司 |
用于治疗变应性和过增生性疾病的咪唑衍生物
|
|
GB0315111D0
(en)
|
2003-06-27 |
2003-07-30 |
Cancer Rec Tech Ltd |
Substituted 5-membered ring compounds and their use
|
|
US20050256179A1
(en)
*
|
2003-08-08 |
2005-11-17 |
Sircar Jagadish C |
Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
|
|
AU2005230867A1
(en)
*
|
2004-03-26 |
2005-10-20 |
Amphora Discovery Corporation |
Certain triazole-based compounds, compositions, and uses thereof
|
|
CA2561718A1
(en)
*
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
|
CN1993332B
(zh)
|
2004-07-27 |
2011-04-06 |
弗·哈夫曼-拉罗切有限公司 |
作为非核苷逆转录酶抑制剂的苄基三唑酮化合物
|
|
US8293778B2
(en)
|
2004-07-27 |
2012-10-23 |
Roche Palo Alto Llc |
Heterocyclic antiviral compounds
|
|
CA2583177A1
(en)
|
2004-10-13 |
2006-04-27 |
Ptc Therapeutics, Inc. |
Compounds for nonsense suppression, and methods for their use
|
|
ES2594874T3
(es)
|
2004-11-18 |
2016-12-23 |
Synta Pharmaceuticals Corp. |
Compuestos de triazol que modulan la actividad de HSP90
|
|
US20080188480A1
(en)
*
|
2005-02-22 |
2008-08-07 |
Cedars-Sinai Medical Center |
Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier
|
|
EP1934185A1
(en)
|
2005-08-12 |
2008-06-25 |
Synta Pharmaceuticals Corporation |
Pyrazole compounds that modulate hsp90 activity
|
|
CA2618724A1
(en)
|
2005-08-18 |
2007-02-22 |
Synta Pharmaceuticals Corp. |
Imidazole compounds that modulate hsp90 activity
|
|
EP1928846B1
(en)
*
|
2005-08-18 |
2014-06-04 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
|
DE102006024024A1
(de)
*
|
2006-05-23 |
2007-11-29 |
Bayer Healthcare Aktiengesellschaft |
Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
|
|
EP2032545A2
(en)
*
|
2006-05-25 |
2009-03-11 |
Synta Pharmaceuticals Corporation |
Compounds that modulate hsp90 activity and methods for identifying same
|
|
AU2007267859B2
(en)
|
2006-05-25 |
2012-04-12 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate Hsp90 activity
|
|
WO2007139968A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
|
TW200804313A
(en)
|
2006-05-25 |
2008-01-16 |
Synta Pharmaceuticals Corp |
Triazole compounds that modulate HSP90 activity
|
|
WO2008087177A1
(en)
*
|
2007-01-18 |
2008-07-24 |
Neurosearch A/S |
Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
|
|
AU2008233929A1
(en)
|
2007-03-29 |
2008-10-09 |
F. Hoffmann-La Roche Ag |
Non-nucleoside reverse transcriptase inhibitors
|
|
US20100137381A1
(en)
*
|
2007-05-03 |
2010-06-03 |
Neurosearch A/S |
Acetamide derivatives as potassium channel modulators
|
|
EP2280948A1
(en)
|
2008-04-09 |
2011-02-09 |
Mitsubishi Tanabe Pharma Corporation |
Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
|
|
US20090281089A1
(en)
*
|
2008-04-11 |
2009-11-12 |
Genentech, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
|
PE20091953A1
(es)
*
|
2008-05-08 |
2010-01-09 |
Du Pont |
Azoles sustituidos como fungicidas
|
|
US9205086B2
(en)
|
2010-04-19 |
2015-12-08 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
|
|
JP2014532712A
(ja)
|
2011-11-02 |
2014-12-08 |
シンタ ファーマシューティカルズ コーポレーション |
トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
|
|
AU2012332424A1
(en)
|
2011-11-02 |
2014-06-05 |
Synta Pharmaceuticals Corp. |
Combination therapy of Hsp90 inhibitors with platinum-containing agents
|
|
AU2012339679A1
(en)
|
2011-11-14 |
2014-06-12 |
Synta Pharmaceuticals Corp. |
Combination therapy of Hsp90 inhibitors with BRAF inhibitors
|
|
WO2013134562A1
(en)
|
2012-03-09 |
2013-09-12 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
AU2013363398B2
(en)
|
2012-12-20 |
2017-06-01 |
Tempest Therapeutics, Inc. |
Triazolone compounds and uses thereof
|
|
MX2016002795A
(es)
|
2013-09-06 |
2016-05-26 |
Inception 2 Inc |
Compuestos de triazolona y usos de los mismos.
|
|
US10681909B2
(en)
|
2014-08-29 |
2020-06-16 |
Fmc Corporation |
Herbicidal triazoles
|
|
CN104710379B
(zh)
*
|
2015-03-09 |
2017-01-18 |
华南理工大学 |
一种bms‑191011的合成方法
|
|
WO2020086149A1
(en)
*
|
2018-10-26 |
2020-04-30 |
University Of South Florida |
Drug for treating tinnitus
|
|
AU2020363366A1
(en)
*
|
2019-10-07 |
2022-04-21 |
D.E. Shaw Research, Llc |
Arylmethylene aromatic compounds as KV1.3 potassium shaker channel blockers
|
|
MX2022004127A
(es)
*
|
2019-10-07 |
2022-06-14 |
De Shaw Res Llc |
Compuestos heterociclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
|
|
CN115504940A
(zh)
*
|
2021-06-23 |
2022-12-23 |
中国科学院上海药物研究所 |
一种酰胺类化合物、其制备方法和制药用途
|